Patents by Inventor Jeffrey Michael Schkeryantz
Jeffrey Michael Schkeryantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230125481Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra1, Ra2, Ra4, Ra5, X1, X1a, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.Type: ApplicationFiled: January 26, 2021Publication date: April 27, 2023Inventors: Christopher John BROWN, James Lindsay CARR, Mohamad SABBAH, Jeffrey Michael SCHKERYANTZ, Daryl Simon WALTER
-
Patent number: 10934280Abstract: The invention provides compounds of the formula: (A), pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds, salts, or compositions to treat hyperphosphatemia, chronic kidney disease, and/or the cardiovascular disease associated with chronic kidney disease.Type: GrantFiled: August 8, 2017Date of Patent: March 2, 2021Assignee: Eli Lilly and CompanyInventors: David Andrew Coates, Kevin Robert Fales, Jeffrey Allen Peterson, Jeffrey Michael Schkeryantz, Quanrong ' Shen, Matthew John Valli, John Rowley Wetterau, II, Dariusz Stanislaw Wodka, Yanping Xu
-
Publication number: 20200031813Abstract: The invention provides compounds of the formula: (A), pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds, salts, or compositions to treat hyperphosphatemia, chronic kidney disease, and/or the cardiovascular disease associated with chronic kidney disease.Type: ApplicationFiled: August 8, 2017Publication date: January 30, 2020Inventors: David Andrew Coates, Kevin Robert Fales, Jeffrey Allen Peterson, Jeffrey Michael Schkeryantz, II, Quanrong ` Shen, Matthew John Valli, John Rowley Wetterau, II, Dariusz Stanislaw Wodka, Yanping Xu
-
6-substituted-3-1,3-benzothiazol-2-one compounds as TARP-gamma 8 dependent AMPA receptor antagonists
Patent number: 9469632Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.Type: GrantFiled: May 21, 2015Date of Patent: October 18, 2016Assignee: Eli Lilly and CompanyInventors: Kevin Matthew Gardinier, Douglas Linn Gernert, Patric James Hahn, Sean Patrick Hollinshead, Albert Khilevich, Daniel Ray Mayhugh, Paul Leslie Ornstein, Warren Jaye Porter, Jon Kevin Reel, Jeffrey Michael Schkeryantz, Patrick Gianpietro Spinazze, Freddie Craig Stevens, Jeffrey Michael Witkin -
Publication number: 20150344468Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.Type: ApplicationFiled: May 21, 2015Publication date: December 3, 2015Inventors: Kevin Matthew GARDINIER, Douglas Linn GERNERT, Patric James HAHN, Sean Patrick HOLLINSHEAD, Albert KHILEVICH, Daniel Ray MAYHUGH, Paul Leslie ORNSTEIN, Warren Jaye PORTER, Jon Kevin REEL, Jeffrey Michael SCHKERYANTZ, Patrick Gianpietro SPINAZZE, Freddie Craig STEVENS, Jeffrey Michael WITKIN
-
Patent number: 7858646Abstract: The present invention provides compounds of formula (I); pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.Type: GrantFiled: November 15, 2005Date of Patent: December 28, 2010Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Dana Rae Benesh, Maria-Jesus Blanco-Pillado, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsäter, Jeffrey Michael Schkeryantz, Tony Pisal Tang
-
Patent number: 7816523Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: GrantFiled: August 28, 2009Date of Patent: October 19, 2010Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang
-
Patent number: 7803938Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: GrantFiled: August 28, 2009Date of Patent: September 28, 2010Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Micheal Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang
-
Patent number: 7754742Abstract: The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.Type: GrantFiled: July 14, 2009Date of Patent: July 13, 2010Assignee: Eli Lilly and CompanyInventors: Albert Khilevich, Bin Liu, Daniel Ray Mayhugh, Jeffrey Michael Schkeryantz, Deyi Zhang
-
Patent number: 7678794Abstract: The present invention provides a compound of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes for preparing the same, and intermediates thereof.Type: GrantFiled: November 15, 2005Date of Patent: March 16, 2010Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang
-
Publication number: 20100016373Abstract: The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.Type: ApplicationFiled: July 14, 2009Publication date: January 21, 2010Inventors: Albert Khilevich, Bin Liu, Daniel Ray Mayhugh, Jeffrey Michael Schkeryantz, Deyi Zhang
-
Publication number: 20090318483Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: ApplicationFiled: August 28, 2009Publication date: December 24, 2009Inventors: Thomas Daniel AICHER, Guillermo S. CORTEZ, Todd Micheal GROENDYKE, Albert KHILEVICH, James Allen KNOBELSDORF, Fredrik Pehr MARMSATER, Jeffrey Michael SCHKERYANTZ, Tony Pisal TANG
-
Publication number: 20090318481Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: ApplicationFiled: August 28, 2009Publication date: December 24, 2009Inventors: Thomas Daniel AICHER, Guillermo S. CORTEZ, Todd Michael GROENDYKE, Albert KHILEVICH, James Allen KNOBELSDORF, Fredrik Pehr MARMSATER, Jeffrey Michael SCHKERYANTZ, Tony Pisal TANG
-
Patent number: 7598423Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: GrantFiled: November 15, 2005Date of Patent: October 6, 2009Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang, Nicholas Andrew Magnus
-
Patent number: 7528160Abstract: The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.Type: GrantFiled: December 31, 2003Date of Patent: May 5, 2009Assignee: Eli Lilly and CompanyInventors: Scott Eugene Conner, James Allen Knobelsdorf, Nathan Bryan Mantlo, Daniel Ray Mayhugh, Xiaodong Wang, Guoxin Zhu, Jeffrey Michael Schkeryantz
-
Publication number: 20080139505Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.Type: ApplicationFiled: November 15, 2005Publication date: June 12, 2008Inventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang, Nicholas Andrew Magnus
-
Patent number: 7153878Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I. (Formula I); wherein: (a) R5 is selected from the group consisting of (C1–C6)alkyl, (C1–C6)alkenyl, aryl (C0–C4)alkyl, aryloxy(C0–C4)alkyl, arylthio(C0–C4)alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C1–C5alkyl, C1–C5alkenyl, and arylC0–C3alkyl.Type: GrantFiled: February 13, 2003Date of Patent: December 26, 2006Assignee: Eli Lilly and CompanyInventors: Scott Eugene Conner, James Allen Knobelsdorf, Nathan Bryan Mantlo, Jeffrey Michael Schkeryantz, Quanrong Shen, Alan M Warshawsky, Guoxin Zhu